CN111050801B - 用于治疗癌症的增加bcl2-相关的细胞死亡激动剂表达的药剂 - Google Patents

用于治疗癌症的增加bcl2-相关的细胞死亡激动剂表达的药剂 Download PDF

Info

Publication number
CN111050801B
CN111050801B CN201880035530.6A CN201880035530A CN111050801B CN 111050801 B CN111050801 B CN 111050801B CN 201880035530 A CN201880035530 A CN 201880035530A CN 111050801 B CN111050801 B CN 111050801B
Authority
CN
China
Prior art keywords
cancer
bad
agent
beta
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880035530.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN111050801A (zh
Inventor
A·达尔格利什
W·吕
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ldn Pharmaceutical Co ltd
Original Assignee
Ldn Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1704910.7A external-priority patent/GB201704910D0/en
Priority claimed from GBGB1718806.1A external-priority patent/GB201718806D0/en
Application filed by Ldn Pharmaceutical Co ltd filed Critical Ldn Pharmaceutical Co ltd
Publication of CN111050801A publication Critical patent/CN111050801A/zh
Application granted granted Critical
Publication of CN111050801B publication Critical patent/CN111050801B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201880035530.6A 2017-03-28 2018-03-28 用于治疗癌症的增加bcl2-相关的细胞死亡激动剂表达的药剂 Active CN111050801B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1704910.7A GB201704910D0 (en) 2017-03-28 2017-03-28 High dose combi I
GB1704910.7 2017-03-28
GBGB1718806.1A GB201718806D0 (en) 2017-11-14 2017-11-14 Breast cancer treatment
GB1718806.1 2017-11-14
PCT/GB2018/050843 WO2018178690A1 (en) 2017-03-28 2018-03-28 An agent that increases the expression of the bcl2-associated agonist of cell death for the treatment of cancer

Publications (2)

Publication Number Publication Date
CN111050801A CN111050801A (zh) 2020-04-21
CN111050801B true CN111050801B (zh) 2023-03-28

Family

ID=61952738

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880035530.6A Active CN111050801B (zh) 2017-03-28 2018-03-28 用于治疗癌症的增加bcl2-相关的细胞死亡激动剂表达的药剂

Country Status (9)

Country Link
US (1) US12611405B2 (https=)
EP (1) EP3600433B1 (https=)
JP (2) JP7657590B2 (https=)
KR (2) KR20200072445A (https=)
CN (1) CN111050801B (https=)
AU (1) AU2018244806B2 (https=)
CA (1) CA3083850A1 (https=)
ES (1) ES2897790T3 (https=)
WO (1) WO2018178690A1 (https=)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030139352A1 (en) * 2001-10-30 2003-07-24 Schoenhard Grant L. Inhibitors of ABC drug transporters in cancer cells

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4689332A (en) 1984-04-09 1987-08-25 Research Corporation Growth regulation and related applications of opioid antagonists
US6384044B1 (en) 1999-11-29 2002-05-07 Bernard Bihari Method of treating cancer of the prostate
DE60119696T2 (de) 2000-03-15 2007-01-25 Wolfgang Ross Sadee Naloxon- und naltrexon-analoga in der behandlung bei drogenmissbrauch
EP1479381A1 (en) * 2003-05-19 2004-11-24 Euro-Celtique S.A. Pharmaceutical dosage form comprising a solid solution
AU2005266090A1 (en) 2004-07-23 2006-02-02 Pfizer Inc. Pyridine derivatives
JP2008538748A (ja) 2005-04-07 2008-11-06 ハイシアム， インコーポレイテッド 不安、物質乱用及び依存の予防のための改良型方法及び組成物
US20070117827A1 (en) * 2005-07-27 2007-05-24 Gary Tollefson Compositions for affecting weight loss
WO2010033890A1 (en) * 2008-09-22 2010-03-25 Mallinckrodt Inc. Polymorphs of 6-beta-naltrexol
SMT201700232T1 (it) * 2010-12-03 2017-07-18 Orexigen Therapeutics Inc Aumento della biodisponibilita' farmacologica nella terapia con naltrexone
JP2015107918A (ja) 2012-02-14 2015-06-11 国立研究開発法人国立がん研究センター 抗がん剤の作用を増強する医薬組成物、がん治療用キット、診断薬、及びスクリーニング方法
GB201308440D0 (en) * 2013-05-10 2013-06-19 Dalgleish Angus Therapeutic
JP6686013B2 (ja) 2014-10-17 2020-04-22 サリックス ファーマスーティカルズ，インコーポレーテッド 腫瘍の進行を減弱させるためのメチルナルトレキソンの使用
GB201704911D0 (en) * 2017-03-28 2017-05-10 Ldn Pharma Ltd High dose combo I

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030139352A1 (en) * 2001-10-30 2003-07-24 Schoenhard Grant L. Inhibitors of ABC drug transporters in cancer cells

Also Published As

Publication number Publication date
AU2018244806B2 (en) 2023-12-21
CN111050801A (zh) 2020-04-21
KR20200072445A (ko) 2020-06-22
JP2025027084A (ja) 2025-02-26
JP7657590B2 (ja) 2025-04-07
WO2018178690A1 (en) 2018-10-04
KR20240125082A (ko) 2024-08-19
CA3083850A1 (en) 2019-10-04
US12611405B2 (en) 2026-04-28
US20200101066A1 (en) 2020-04-02
ES2897790T3 (es) 2022-03-02
EP3600433B1 (en) 2021-05-05
AU2018244806A1 (en) 2019-11-21
EP3600433A1 (en) 2020-02-05
JP2020515649A (ja) 2020-05-28

Similar Documents

Publication Publication Date Title
JP7323592B2 (ja) 癌を治療するための併用療法
US10959984B2 (en) Methods for treating cancer with RORγ inhibitors
US11351165B2 (en) Agent that increases the expression of the opioid kappa 1 for the treatment of cancer
JP2022524885A (ja) ナルトレキソン及びカンナビノイドを含む癌の治療
JP6620338B2 (ja) 低用量ナルトレキソンによるがん細胞の準備刺激
Abdelaal et al. Reversing oncogenic transformation with iron chelation
WO2015061832A1 (en) Pharmaceutical combinations for the treatment of cancer
TW201722422A (zh) 用於治療癌症之合理組合療法
CN111050801B (zh) 用于治疗癌症的增加bcl2-相关的细胞死亡激动剂表达的药剂
JP7282072B2 (ja) 肺がんの治療に使用するための組み合わせ
US9566334B2 (en) Combinations of a PI3K/AKT inhibitor compound with an HER3/EGFR inhibitor compound and use thereof in the treatment of a hyperproliferative disorder
US20220409582A1 (en) Combination therapies comprising panobinostat for the treatment of cholangiocarcinoma
WO2015153866A1 (en) Cancer therapy with ganetespib and an egfr inhibitor
CN102781444A (zh) 用于治疗肝细胞癌的抗肿瘤剂或手术后辅助化学治疗剂
WO2026039849A1 (en) Nuclear transport inhibitors for anti-cancer combination therapy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant